Large-scale genome sequencing is poised to provide an exponential increase in the discovery of disease-associated mutations, but the functional interpretation of such mutations remains challenging. Here we identify deletions of a sequence termed intestine-critical region (ICR) on chromosome 16 that cause intractable congenital diarrhea in infants 1, 2 . Transgenic mouse reporter assays show that the ICR contains a regulatory sequence that activates transcription during development of the gastrointestinal system. Targeted deletion of the ICR in mice caused symptoms recapitulating the human condition. Transcriptome analysis uncovered an unannotated open reading frame (Percc1) flanking the regulatory sequence whose expression was lost in the developing gut of ICR knockout animals. Targeted deletion of the Percc1 gene in mice caused phenotypes similar to those observed upon ICR deletion in mice and patients, whereas an ICR-driven Percc1 transgene was sufficient to rescue the phenotypes found in ICR knockout mice. Taken together, our results identify a novel human gene critical for intestinal function and underscore the need for targeted in vivo studies for interpreting the growing number of clinical genetic findings that do not affect known protein-coding genes.
In contrast to whole exome sequencing (WES) 3 , whole genome sequencing (WGS) can in principle identify mutations in noncoding sequences, as well as in genes that are not annotated in the reference genome. However, sequence variation affecting poorly annotated sequences outside of known genes is challenging to interpret because of the lack of structural and functional annotation of these regions. In the present study, we demonstrate how the identification of noncoding deletions in a small number of patients coupled to purpose-built mouse models can elucidate the regulatory and genic basis of an inherited severe disease ( Fig. 1 ).
Congenital diarrheal disorders are a heterogeneous group of inherited diseases of the digestive system and are frequently life-threatening if untreated 1,2,4 (see Suppl. Text for additional clinical background). We studied eight patients from seven unrelated families of common ethnogeographic origin with an autosomal recessive pattern of severe congenital malabsorptive diarrhea named IDIS (for Intractable Diarrhea of Infancy Syndrome) 2 (Fig.  1a,b ; Extended Data Fig. 1 ; Suppl. Text). Initial WES analysis revealed no rare exonic sequence variants with the appropriate patient segregation. However, whole genome linkage analysis and haplotype reconstruction detected a single significant telomeric linkage interval on chromosome 16 (LOD = 4.26; Extended Data Fig. 2a , see Suppl. Text). We examined WES and WGS data from selected patients and observed a 7,013 bp deletion, termed ΔL, in the absence of other structural changes or coding mutations at the affected locus ( Fig. 1c , Extended Data Fig. 1 and 2b , Suppl. Text). Two of the patients (4.1 and 4.2) were compound heterozygous for ΔL, along with a second variant, termed ΔS, which contains a 3,101 bp deletion that partially overlaps ΔL, defining a minimal sequence termed intestine-critical region (ICR) of 1,528 bp (Fig. 1c ). All eight patients in this study showed ICR ΔS/ΔS , ICR ΔS/ΔL or ICR ΔL/ΔL genotypes, resulting in a homozygous deletion of the ICR that was not detected in any of the control groups examined (Extended Data Fig. 1 , Suppl. Text). These data suggest that the deletion of the ICR causes the congenital diarrhea phenotype.
To explore possible noncoding functions of the ICR, we examined Encyclopedia of DNA Elements (ENCODE) data 5 . The ICR contains a 400 bp region with high evolutionary conservation across vertebrates, includes CpG island and DNase hypersensitivity signatures, and encompasses a cluster of multiple binding sites for transcription factors including FOXA1 and FOXA2 6, 7 (Fig. 1c) . To test the hypothesis that the ICR contains a regulatory sequence, we examined its in vivo activity in a transgenic mouse reporter assay 8 . In transgenic embryos ranging from embryonic day (E) 11.5 to E14.5, we observed robust and reproducible reporter activity in the stomach, pancreas, and duodenum ( Fig. 2a,b) . These results support the notion that the ICR lost in congenital diarrhea patients contains a gene regulatory sequence that is active in the developing digestive system.
To examine if loss of the ICR sequence is sufficient to cause the phenotypes observed in human patients, we deleted a 1,512 bp interval from the mouse genome that included the mouse orthologues of the human DNase hypersensitivity signature and predicted FOXA1/2 binding sites ( Fig. 1d , Extended Data Fig. 3 ). Homozygous chr17 ΔICR/ΔICR pups were born at the expected Mendelian frequency and showed no gross phenotypes at birth. However, starting within the first few days of life, chr17 ΔICR/ΔICR mice displayed overall reduced size (Figs. 1e, 2c), low body weight (Fig. 2d ), and substantially decreased survival ( Fig. 2e ). Examination of fecal pellets and internal organs revealed abnormal digestive tract function in chr17 ΔICR/ΔICR mice ( Fig. 1f ; Extended Data Fig. 4a ), as well as changes in the composition of the intestinal microbiome in chr17 ΔICR/ΔICR mice (Extended Data Fig. 4b ; Suppl. Text). Our combined results indicate that deletion of the ICR in mice causes disruption of intestinal function, recapitulating the congenital diarrhea phenotype observed in human patients carrying homozygous ICR deletions.
Next, we sought to elucidate the molecular mechanisms through which deletion of the ICR causes deficiencies in gastrointestinal function. Targeted expression analysis of stomach and intestinal mouse tissue samples covering developmental stages ranging from E14.5 to P20 revealed an unannotated region flanking the ICR that showed very low levels of expression in wildtype prenatal stomach tissue ( Fig. 3a ). Expression of this sequence was completely lost in matched tissues from chr17 ΔICR/ΔICR littermates, suggesting the presence of a gene previously unannotated in both the human and mouse genomes (Extended Data Fig. 3c ). Sequence analysis identified an 897-bp open reading frame predicted to encode a protein that is Proline and glutamate (E) Rich and contains an N-terminal Coiled Coil domain (PERCC1, Fig. 3b ). Despite overall strong evolutionary conservation across vertebrates ( Fig.  3c ), PERCC1 homology-and structure-based searches failed to identify similarities to known proteins. However, comparison of human and mouse non-synonymous and synonymous substitutions showed a dN/dS ratio of 0.17, further supporting that PERCC1 represents a bona fide protein-coding gene ( Fig. 3d ).
To compare the spatiotemporal expression of mouse Percc1 with the regulatory in vivo activity of the ICR, we performed mRNA in situ hybridization for Percc1. At E14.5, we observed a pattern of punctate Percc1 expression in stomach, pancreas, and intestine highly reminiscent of ICR activity (Extended Data Fig. 5, Fig. 2a,b) . To further establish a functional connection between the ICR regulatory sequence and the predicted open reading frame, we used genome editing to disrupt the Percc1 open reading frame in mice. Percc1 −/− mice mimicked the key phenotypes of chr17 ΔICR/ΔICR mice, including low body weight (Extended Data Fig. 6a ) and abnormal appearance of intestinal content (n=11/12 [92%] in Percc1 −/− ; n=20/21 [95%] in chr17 ΔICR/ΔICR ; p=0.7, two-tailed T-test). Finally, to establish that Percc1 expression is sufficient to rescue the phenotypes resulting from deletion of the ICR regulatory sequence, we performed a complementation experiment in which we generated chr17 ΔICR/ΔICR mice with an ICR-Percc1 transgene. Upon complementation, we observed reversal of the reduced body weight, high lethality, and intestinal dysfunction found in chr17 ΔICR/ΔICR mice (Extended Data Fig. 6b ). These results establish that lack of gastrointestinal expression of PERCC1, normally controlled by the ICR, causes the phenotypes observed in chr17 ΔICR/ΔICR mice and likely in IDIS patients examined in this study.
To explore the cell type specificity and function of PERCC1, we generated a transgenic mouse line encoding a PERCC1-mCherry fusion protein ( Fig. 4a , Extended Data Fig. 7 ). At postnatal day 8, some PERCC1-mCherry positive (PERCC1 + ) cells were detected in the epithelium of the intestinal villi (Extended Data Fig. 7c ), whereas distal stomach compartments displayed a high density of strongly positive cells, in particular in the epithelial layers of the pylorus, antrum, and corpus ( Fig. 4a , Extended Data Fig 7b) . Colocalization with the pan-endocrine marker Synaptophysin (SYP) revealed that a major fraction of PERCC1-positive cells in these compartments are endocrine cells ( Fig. 4a , Extended Data Fig. 7c ). The vast majority of PERCC1 + cells detected in the antral epithelium were Gastrin-expressing G-cells ( Fig. 4a ), which are required for secretion of gastric acid and promote growth of the gastrointestinal tract 9 . In contrast, the glandular epithelium at the entrance to the pyloric canal also contained clusters of PERCC1 + cells without endocrine signatures located at the gland base, a region known to harbor gastric stem cells 10 (Fig. 4a ). As the majority of PERCC1 + cells in the distal stomach were G-cells, we next investigated whether loss of Percc1 in mice affected the development of these cells.
We observed that the number of Gastrin-expressing cells was reduced in the absence of Percc1 (Extended Data Fig. 7d ). Finally, analysis of 11,665 single cell transcriptomes from mouse intestinal epithelium 11 showed that Percc1 is expressed in a small proportion of cells that are strongly enriched for enteroendocrine cells (EECs; p = 2.9e-20, chi-squared test, Extended Data Fig. 8a ). Percc1-positive cells express Sox4 and Neurog3, and their expression profiles are most consistent with an enteroendocrine progenitor identity (Extended Data Fig. 8b, c) . These data indicate that expression of PERCC1 in gastrointestinal tissue is restricted primarily to gastric G-cells and duodenal enteroendocrine cells, and suggest that disrupted development of these cells causes the observed phenotype.
To characterize the molecular consequences of loss of the ICR or Percc1 in more detail, we examined RNA-seq data from relevant stages of mouse development. Among the 100 genes showing the greatest reduction in expression, seven encode gastrointestinal peptide hormones secreted by EECs 12 (Figure 4b , Table 1 , Suppl. Table S1 ). Strikingly, reduction of Gastrin expression (Gast) appears as one of the most robust changes, along with changes in Somatostatin (Sst) and Ghrelin (Ghrl) expression ( Figure 4d, e ). We observed similar gene expression changes in duodenal and stomach biopsies obtained from an ICR ΔL/ΔL patient and an unaffected ICR +/+ sibling ( Table 1 ; Suppl. Table S2 ; Extended Data Fig. 9 ). Together, these results are consistent with major disruptions of normal gastrointestinal physiology in chr17 ΔICR/ΔICR mice and human IDIS patients and highlight the close resemblance between the human disease condition and our mouse knockout models.
We also generated induced pluripotent stem cells (iPSC) from an ICR ΔL/ΔL patient and an unaffected ICR +/+ sibling and differentiated them into human intestinal organoids (HIOs) (Extended Data Fig. 10 ) 13 . The gross morphology of ICR ΔL/ΔL and control ICR +/+ HIOs was overall similar and at early stages (21 days) the ICR ΔL/ΔL HIOs revealed an abundant presence of EECs (Extended Data Fig. 7e ). In contrast, by day 42 the ICR ΔL/ΔL HIOs showed a severe reduction in the number of EECs compared to control HIOs, along with reduced expression of EEC markers Chromogranin A (CHGA) and Synaptophysin (SYP) ( Fig. 4c ; Extended Data Fig. 7e ). These results suggest that disruption of the ICR is compatible with the initial formation of EECs, but interferes with their subsequent development.
Limited understanding of the in vivo function of human protein-coding genes and noncoding sequences continues to be a grand challenge preventing the systematic interpretation of disease-related data from WES and WGS studies. In the present work we establish that IDIS, a severe, recessively inherited gastrointestinal disease, is caused by microdeletions that disrupt a regulatory sequence required for normal intestinal expression of the previously unannotated PERCC1 gene. The molecular, cellular, and physiological phenotypes observed in human patients and engineered mice indicate that PERCC1 is required for normal development of EECs and, thereby, normal enteroendocrine hormone secretion. The phenotype of chr17 ΔICR/ΔICR mice resembles that of mice with an intestinal-specific deletion of Neurog3, a proendocrine transcription factor required for development of EECs 14 , further supporting abnormal EEC development as the cause of IDIS. The different etiologies of chronic diarrhea of infancy and enteropathies have recently been reviewed and classified into distinct categories 15 . Among these categories, disorders of enteroendocrine cell function, caused by mutations in Neurog3, Arx, Pcsk1, Rfx6, are described as a unique and separate entity that manifest with malabsorptive diarrhea. The phenotypes observed in human patients and engineered mice indicate that IDIS is most similar to this specific class of chronic diarrheal disorders. Beyond congenital diarrhea, our results serve as a reminder that, despite extensive annotation efforts, protein-coding genes associated with disease phenotypes remain to be discovered. As WGS is increasingly used for studies of rare diseases, our work underscores the importance of detailed experimental follow-up of such findings through in vivo models.
Methods

Experimental Design
All animal work was reviewed and approved by the Lawrence Berkeley National Laboratory Animal Welfare Committee. All mice used in this study were housed at the Animal Care Facility (the ACF) at LBNL. Mice were monitored daily for food and water intake, and animals were inspected weekly by the Chair of the Animal Welfare and Research Committee and the head of the animal facility in consultation with the veterinary staff. The LBNL ACF is accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC). Generation of transgenic mice and manipulation of genomic sequence were performed in Mus musculus FVB strain mice, mice with C57/129S6 mixed background or W4/129S6 ES cells (see below for details). Animals of both sexes were used in the analysis. Sample size selection and randomization strategies were conducted as follows:
Transgenic mouse assays.-Sample sizes were selected empirically based on our previous experience of performing transgenic mouse assays for >2,000 total putative enhancers (VISTA Enhancer Browser: https://enhancer.lbl.gov/). Mouse embryos or postnatal mice were excluded from further analysis if they did not contain the reporter transgene or if the stage was not correct. All transgenic mice were treated with identical experimental conditions. Randomization and experimenter blinding were unnecessary and not performed.
Genomic knockouts.-Sample sizes were selected empirically based on our previous studies 16 . All phenotypic characterization of knockout mice employed a matched littermate selection strategy. All phenotyped homozygous knockout mice described in the paper resulted from crossing heterozygous knockout mice together to allow for the comparison of matched littermates of different genotypes. Embryonic samples used for RNA-seq and immunofluorescence were dissected blind to genotype. RNA-seq libraries were prepared and sequenced in mixed batches (including both KO and WT samples).
Subjects: IDIS patients were recruited at Schneider and Sheba medical centers in Israel.
Clinical details of the subjects are provided in Supp. Table S4 . All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants and/or their legal guardian involved in the study.
Exome sequencing and variants identification:
Exome sequencing was performed using Agilent SureSelect Human All Exon technology (Agilent Technologies, Santa Clara, CA). The captured regions were sequenced using Genome Analyzer IIx (Illumina, Inc. San Diego, CA). The resulting reads were aligned to the reference genome (build 37) using the Burrows-Wheeler Alignment (BWA) tool 17 . We obtained 70× coverage, where a base was considered covered if ≥5 reads spanned the nucleotide. Genetic differences relative to the reference genome were identified by the SAMtools v0.1.7a variant calling program 18 , which identifies both single nucleotide variants and small insertion-deletions (indels). Finally, the Sequence Variant Analyzer software (SVA v1.10) 19 was used to annotate all identified variants. For comparison to controls, we utilized 1000 samples subjected to exome or whole genome sequencing at the Center for Human Genome Variation (CHGV, Duke University, NC, USA), dbSNP, 1000 genomes, and NHLBI GO Exome-sequencing Project.
Whole genome sequencing: WGS of individual 2.1 was performed at CHGV, using the Illumina HiSeq platform (Illumina, Inc. San Diego, CA) and analyzed as described for exome data. 275 CHGV whole-genome sequenced, unrelated samples were used as controls. To detect copy number variants from WGS we used the estimation by read depth with single-nucleotide variants (ERDS) tool 20 .
Biopsy collection: Subjects underwent gastro-duodenoscopy following Institutional Review Board (IRB) approval (No. 9881-12-SMC) at Sheba Medical Center and written informed consent of the patients and family members.
RNA extraction from biopsies: RNA isolation from frozen biopsies was performed using TRI Reagent method (Sigma-Aldrich Inc.) according to the manufacturer's instructions or by Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Integrity of the samples was measured for concentration and purity using a NanoDrop Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA).
RNA sequencing of human samples: Total RNA was prepared according to the Illumina RNA-seq protocol. Briefly, globin reduction, polyA enrichment, chemical fragmentation of the polyA RNA, cDNA synthesis, and size selection of 200bp cDNA fragments were performed. Next, the size-selected libraries were used for cluster generation on the flow cell and prepared flow cells were run on the Illumina HiSeq2000 (Illumina, Inc. San Diego, CA). We obtained a total of 74.18 million paired-end reads of 100 bp for the affected sample and 72.53 million reads to the healthy sample. Reads were align to the human genome (NCBI37/hg19) using Tophat v2.0.4 21 with the default parameters. Gene expression quantification was performed with Cuffdiff v2.0.2 21 using the Illumina iGenome project UCSC annotation file as a reference. Differentially expressed genes were defined using the following thresholds: 1.5 fold change, p-value ≤ 0.05.
Quantitative Real-Time Reverse Transcriptase (RT) Polymerase Chain Reaction (qPCR):
RNA extracted from biopsies was used for RT-PCR expression analyses. RT-PCR were performed using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) using the Applied Biosystems StepOnePlus (Applied Biosystems). From 1 μg of biopsy RNA, cDNA was synthesized using the SuperScript® First-strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. A total of 20μl of cDNA was added with 30μl of water to 50μl of TaqMan universal PCR Master Mix (Applied Biosystems) and the resulting 100μl reaction mixtures were loaded onto a 96-well PCR plate. We used 14 different TaqMan Gene Expression Assays including three housekeeping genes with the following assays IDs: Hs00757713_m1 (MLN), Hs01074053_m1 (GHRL), Hs00175048_m1 (NTS), Hs00356144_m1 (SST), Hs00174945_m1 (PYY), Hs01062283_m1 (GAST), Hs00292465_m1 (ARX), Hs00174937_m1 (CCK), Hs00175030_m1 (GIP), Hs00219734_m1 (GKN1), and Hs00699389_m1 (GKN2). The housekeeping genes we used were HMBS (Hs00609297_m1), ACTB (Hs99999903_m1) and GAPDH (Hs99999905_m1). Reference cDNA samples were synthesized using 200 ng of RNA from RNA extracted from stomach and duodenum tissues of two healthy controls (BioCat GmbH, Heidelberg, Germany) for use in the normalization calculations. qPCR for expression analysis on the missing exons in C16ORF91 was done using cDNA extracted from the Human Digestive System MTC Panel (Clontech Laboratories, Inc. Mountain View, CA).
Serum Collection:
Whole blood was withdrawn into a Vacutainer serum tube without anti-coagulant. The blood was immediately treated with 1μM AEBSF (protease inhibitor) and remained at room temparature for 30 min to clot before centrifugation (15 min at 2500 rpm at 4°C).
ELISA: Serum hormone levels were determined using the sandwich ELISA technique performed by the following commercial kits according to the manufacturer's instructions. Human Ghrelin (Total) ELISA COLD PACKS (Millipore, USA), Human PYY (Total) ELISA Kit (Millipore), and Human gastric inhibitory polypeptide (GIP) ELISA Kit (ENCO).
Linkage analysis and homozygosity mapping:
Genome-wide SNP genotyping from DNA of 6 affected children and 22 relatives from families 1-5 was performed using the Illumina HumanCytoSNP-12v2-1_H, according to the manufacturer's recommendations (Illumina, Inc. San Diego, CA) in conjunction with SNP genotypes retrieved from whole exome data. For linkage studies 35,845 informative equally spaced SNP markers were chosen after filtering for Mendelian errors and unlikely genotypes. Genotypes were examined with the use of a multipoint parametric linkage analysis and haplotype reconstruction for an autosomal recessive model with complete penetrance and a disease allele frequency of 0.001 as previously described 22 . Homozygosity mapping was performed using PLINK v1.07 23 with the default parameters (length 1000 kb, SNP(N) 100, SNP density 50 kb/SNP, largest gap 1000 kb).
Deletion analysis:
Boundaries for the two deletion alleles were determined by PCR using amplified DNA and Sanger sequencing. The specific primers used to amplify across both deletions and inside the overlapping region for the two deletions are reported in Supp. Table  S5 . In parallel, we used polymorphic markers that were identified by electronically screening genomic clones located on Chr16 0.86-2.8Mb. Primers were designed with the Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi/ from the Whitehead Institute, Massachusetts Institute of Technology, and Cambridge, MA). The specific primers used are reported in Supp. Table S6 . Amplification of the polymorphic markers was performed in a 25μl reaction containing 50 ng of DNA, 13.4 ng of each primer, and 1.5 mM dNTPs in1.5 mM MgCl 2 PCR buffer with 1.2 U Taq polymerase (Bio-Line, London, UK). After an initial denaturation of 5 min at 95°C, 30 cycles were performed (94°C for 2 min, 56°C for 3 min, and 72°C for 1 min), followed by a final step of 7 min at 72°C. PCR products were electrophoretically separated on an automated genetic analyzer (Prism 3100; Applied Biosystems, Inc.
[ABI], Foster City, CA). The breakpoints coordinates were : ΔL-chr16: 1475365-1482378, ΔS-chr16:1480850-1483951, with an overlapping region at chr16: 1480850-1482378 (ICR).
Mouse transgenic assays:
The candidate gene regulatory sequence (chr 16: 1479875 -1480992) was PCR amplified from human genomic DNA and was cloned into the hsp68-lacZ transgenic vector containing a minimal hsp68 promoter coupled to a lacZ reporter gene.
The purified transgene construct was microinjected into fertilized FVB/N mouse oocytes, which were implanted into pseudopregnant foster females and embryos were collected at E11.5 through E14.5. Transgenic activity was determined by X-gal staining to detect βgalactosidase activity. Only patterns observed in at least three different embryos resulting from independent transgenic events were considered reproducible positive enhancers. All animal work was reviewed and approved by the Lawrence Berkeley National Laboratory Animal Welfare and Research Committee.
Generation of ICR knockout mice (chr17 ΔICR/ΔICR ):
Homologous arms were generated by PCR (see Suppl. Table S7 for primers) and cloned into the ploxPN2T vector, which contains a neomycin (G418)-resistant cassette flanked by loxP sites for positive selection, and an HSV-tk cassette for negative selection. Constructs were linearized and electroporated (20μg) into W4/129S6 mouse embryonic stem cells (Taconic). The electroporated cells were selected under G418 (150μg/ml) and 0.2μM FIAU for a week. Surviving colonies were picked and expanded on 96-well plates, screened by PCR and sequencing with primers outside but flanking the homology arm. Clones that were correctly targeted were electroporated with 20μg of the Cre recombinase-expressing plasmid TURBO-Cre. TURBO-Cre was provided by Dr. Timothy Ley of the Embryonic Stem Cell Core of the Siteman Cancer Center, Washington University Medical School. Clones positive for Neo removal were screened by PCR and checked for G418 sensitivity. PCR products covering the deleted region and part of homologous arms were gel purified and sequenced to confirm the deletion of the ICR. Correctly targeted clones were subsequently injected into C57BL/6J blastocyst stage embryos. Chimeric mice were then crossed to C57BL/6J mice (Charles River) as well as 129S6/SvEvTac (Taconic) to generate heterozygous ICR-null mice, followed by breeding of heterozygous littermates to generate homozygous null mice.
Genotyping of chr17 ΔICR mice: Genomic DNA was extracted from a 0.2 to 0.3-cm section of tail that was incubated overnight in lysis buffer (containing 100mM Tris-HCl pH 8.5, 5mM EDTA, 0.2% SDS, 200mM NaCl and 50μg Proteinase K) at 55°C. Genotyping was carried out using standard PCR techniques (see Suppl. Table S7 for primers). 1-2μl of 50-to 100-fold diluted tail lysate was used in a 20μl PCR containing 200 μM dNTP, 1.5 mM MgCl 2 , 5 pmole of each forward and reverse primer and 0.5U of Taq polymerase.
RNA sequencing of mouse tissues: Total RNA was extracted from different intestinal regions and stomach of mice at E11.5, P1, P5, P10, P15 and P20 using TRIzol Reagent (Invitrogen). RNAseq libraries were then constructed using Illumina TruSeq Stranded Total RNA Sample Preparation Kit following manufacturer's recommendation. The libraries were sequenced using a 50bp single end strategy with four samples per lane on an Illumina HiSeq instrument, and data were analyzed using the same protocols as described for human, though with the mm9 mouse reference and Illumina iGenome project mouse genome annotation data. The RNA-seq data can be accessed under GEO number GSE94245. DAVID v6.7 24 was run separately on the differentially expressed genes in the P10 stomach (167 downregulated, 187 up-regulated, Supp. Table S1) or in the P10 intestine (326 down-regulated, 327 up-regulated, Supp. Table S1 ). The resulting lists of clustered terms were inspected for highly significant enrichment (q-value ≤0.05) for biological process (GO), molecular function (MF), or pathway (KEGG) (see Supp. Table S3 ). The most significant term for each cluster was retained. In total, 59 genes showing any of these annotations were also found in the top 100 deregulated genes (either up-or down-regulated, separately for each tissue). A selection of genes from these 59 is highlighted in Table 1 .
16S amplicon analysis (iTags) of microbial community diversity:
Feces and gut content samples were collected from chr17 ΔICR/ΔICR mice and wild type littermates. DNA was extracted from these samples using PowerFecal DNA Isolation Kit (MO Bio Laboratories). V4 16S regions were amplified from the DNA samples using barcoded primers and 5 PRIME™ HotMasterMix (Fisher Scientific) as previously described 25 . Amplicons were pooled in equal amount, purified with AMPureXP magnetic beads (Beckman Coulter), and sequenced. Percc1 knockout mice by CRISPR/Cas9: Percc1 knockout mice were generated by CRISPR/Cas9 editing as previously described 26, 27 . Single guide RNAs (sgRNAs) were constructed using 60-mer oligonucleotides and an sgRNA cloning vector (Addgene plasmid 41824) 28 according to the following protocol: http://www.addgene.org/static/cms/files/ hCRISPR_gRNA_Synthesis.pdf. The sgRNA target site sequences are provided in Supp. Table S9 . Cas9 mRNA was generated using a human codon-optimized Cas9 gene from plasmid pDD921 29 . T7-promoter-Cas9-polyA and T7-promoter-sgRNA amplicons were PCR amplified from pDD921 and sgRNA clones, respectively, using Phusion polymerase (New England Biolabs). Cas9 RNA was generated by in vitro transcription from the T7promoter-Cas9-polyA amplicon using mMESSAGE mMACHINE T7 Kit (ThermoFisher 
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Scientific), following the manufacturer's instructions. sgRNA RNA was generated by in vitro transcription from the T7-promoter-sgRNA amplicon using MEGAshortscript Kit (ThermoFisher Scientific), following manufacturer's instructions. In vitro-transcribed RNA was cleaned using MEGAclear Kit (ThermoFisher Scientific), following the manufacturer's instructions. RNA was eluted into RNase-free microinjection buffer (10 mM Tris, pH7.5; 0.1 mM EDTA). The RNA was then assessed by electrophoresis on a 10% TBE Urea PAGE gel.
Microinjection and generation of genetically modified mice: A mixture of 100 ng/ μl Cas9 RNA and 50 ng/μl total sgRNA RNAs in microinjection buffer was injected into cytoplasm of fertilized mouse strain FVB/N mouse oocytes. Pups generated (F0) were screened by PCR (primers listed in Supp. Table S9 ) and resulting PCR products were sequenced to identify deletion breakpoints.
Complementation of chr17 ΔICR/ΔICR with a Percc1 mouse transgene: An 8530bp region was PCR-amplified from W4/129S6 mouse genomic DNA (primer sequences can be found in Suppl. Table S10 ). The region amplified includes all putative Percc1 exons, a possible promoter, and the 3'-UTR. The resulting PCR product was cloned into pCR2.1 vector (Invitrogen TOPO® TA Cloning® Kit) and verified by sequencing. To generate transgenic mice, a purified, linear transgene fragment was injected into the pronucleus of fertilized eggs from chr17 ΔICR/+ intercrosses. Offspring were PCR genotyped for existence of the Percc1 transgene and examined for phenotypes found in chr17 ΔICR/ΔICR mice.
Generation of PERCC1-mCherry fusion protein transgenic mice:
A 3308bp fragment covering the Percc1 promoter to the last amino acid of the Percc1 coding region was PCR amplified and cloned into the pcDNA3 mCherry LIC cloning vector 6B (Addgene, #30125) 5' of the mCherry cDNA to generate a mouse Percc1-mCherry fusion construct (primers can be found in Suppl. Table S11 ). The construct was linearized with NotI and injected into the pronucleus of fertilized FVB eggs to generate transgenic mice. . Gastrin-positive cells were counted on consecutive stomach sections of wild-type (N=3) and ICR knockout (N=2) mice at P8. The fraction of gastrin-expressing cells was calculated by normalization to the total number of nuclei determined via Cell Profiler (http:// cellprofiler.org). Cell counts from each antral side (as shown in the schematic of Extended Data Figure 11c ) were averaged.
Mouse Intestine Single Cell Analysis:
Single-cell RNA-seq profiles 11 were retrieved from the Gene Expression Omnibus 30 (GEO, GSE92332). SAM alignment files 18 were downloaded from the Short Read Archive using the sam-dump utility (part of the SRA Toolkit v2.8.1, http://ncbi.github.io/sra-tools/). Coordinates of the reads mapping to Percc1 were extracted using SAMtools v1.3.1 18 , along with the corresponding cell barcodes and UMIs (CB:Z and UB:Z, respectively). These allowed the assignment of each unique transcript (via UMI) to the parental cell (via cell barcode). Cell-type classification as described in Haber et al 11 . were parsed from GSE92332_Regional_UMIcounts.txt.gz (available on the GEO, GSE92332). All the further data processing steps, plots and p-values calculations were performed in the statistical computing environment R v.3.4.2 (www.rproject.org).
Histological analysis of human biopsies: FFPE blocks were sectioned at a thickness of 4μm and a positive control was added on the right side of the slides. All immunostainings were fully calibrated on a Benchmark XT staining module (Ventana Medical Systems Inc., USA). Briefly, after sections were dewaxed and rehydrated, a CC1 Standard Benchmark XT pretreatment for antigen retrieval (Ventana Medical Systems) was selected for all immunostainings: Chromogranin A (1:500, Dako, Denmark), Synaptophysin, (1:200, Life Technologies, Invitrogen, USA), GAST, CGC and STT. Detection was performed with iView DAB Detection Kit (Ventana Medical Systems Inc., USA) and counterstained with hematoxylin (Ventana Medical Systems Inc., USA). After the run on the automated stainer was completed, slides were dehydrated in ethanol solutions (70%, 96%, and 100%) for one min each. Sections were then cleared in xylene for 2 min, mounted with Entellan and cover slips were added.
Generation of induced pluripotent stem cells (iPSCs) from patient lymphocytes:
Whole blood was isolated by routine venipuncture from patient 2.1 and two healthy siblings (2.3-heterozygous carrier, 2.4-unaffected WT) at Sheba Medical Center in Israel, in preservative-free 0.9% sodium chloride containing 100U/ml heparin. Blood was then shipped overnight to Cincinnati Children's Hospital Medical Center for iPS cell generation. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll centrifugation as previously described 28 and were used to derive iPSCs. Briefly, PBMCs were cultured for 4 d in DMEM containing 10% FCS, 100ng/ml SCF, 100ng/ml TPO, 100ng/ml IL3, 20ng/ml IL6, 100ng/ml Flt3L, 100ng/ml GM-CSF, and 50ng/ml M-CSF (Peprotech). Transduction using a polycistronic lentivirus expressing Oct4, Sox2, Klf4, cMyc and dTomato was performed 31 following the second day of culture in this media. Transduced cells were then cultured for an additional 4 d in DMEM containing 10% FCS, 100ng/ml SCF, 100ng/ml TPO, 100ng/ml IL3, 20ng/ml IL6, and 100ng/ml Flt3L. Media was changed every other day. PBMCs were then plated on 0.1% gelatin-coated dishes containing 2 × 10 4 irradiated MEFs/cm 2 (GlobalStem, Rockville, MD), and cultured in hESC media containing 20% knockout serum replacement, 1mM L-glutamine, 0.1mM βmercaptoethanol, 1× non-essential amino acids, and 4ng/ml bFGF until iPSC colony formation. Putative iPSC colonies were then manually excised and re-plated in feeder free culture conditions consisting of matrigel (BD BioSciences, San Jose, CA) and mTeSR1 (STEMCELL Technologies, Vancouver, BC). Lines exhibiting robust proliferation and maintenance of stereotypical human pluripotent stem cell morphology were then expanded and cryopreserved before use in experiments. Standard metaphase spreads and G-banded karyotypes were determined by the CCHMC Cytogenetics Laboratory.
Differentiation of iPSCs into intestinal organoids:
The differentiation of induced human pluripotent stem cells was performed as previously described 13, 32, 33 with minor modifications. Briefly, two clonal iPSC lines from each donor were dispase passaged into a matrigel-coated 24-well tissue culture plate and cultured for 3 d in mTeSR1. Following definitive endoderm differentiation, the monolayers were treated for 4 d with RPMI medium 1640 (Gibco) containing 2% defined fetal calf serum, 1× non-essential amino acids, 3μM CHIR99021 (Stemgent) and 500ng/ml rhFGF4 (R&D Systems) to induce hindgut spheroid morphogenesis. After the 4 th day, "day 0" HIOs were collected and embedded in matrigel matrix and cultured in Advanced DMEM/F12 (Gibco) containing 100 U/ml penicillin/ streptomycin (Gibco), 2mM L-Glutamine (Gibco), 15mM HEPES (Gibco), N2 Supplement (Gibco), B27 Supplement (Gibco), and 100ng/mL rhEGF (R&D Systems) for up to 42 days, splitting, passaging, and changing the media periodically.
HIOs collected for immunofluorescence analysis were fixed in 4% paraformaldehyde for 1-2 h at room temperature, washed overnight at 4°C in PBS, and embedded in O.C.T. Compound (Sakura). 8-10μm thick sections were incubated with primary antibodies overnight at 4°C in 10% normal donkey serum, 0.05% Triton X-100-PBS solution and subsequently incubated with secondary antibodies for 1 h at room temperature. The primary antibodies used were: FoxA2 (1:500; Novus), E-Cadherin (1:500; R&D Systems), Synaptophysin (1:1000; Synaptic Systems), CDX2 (1:500; Biogenex), Pdx1 (1:5000; Abcam). All secondary antibodies (AlexaFluor; Invitrogen) were used at 1:500 dilution. Confocal microscopy images were captured with a 20× plan apo objective on a Nikon A1Rsi Inverted, using settings of 0.5 pixel dwell time, 1024 resolution, 2× line averaging, and 2.0× A1 plus scan.
Total RNA was extracted from HIOs using a NucleoSpin RNA II kit (Macherey-Nagel), and cDNA was synthesized with SuperScript VILO (Invitrogen) using 300ng RNA. qPCR analysis was performed with TaqMan Fast Advanced Master Mix and custom designed TaqMan Array 96-Well FAST Plates (Applied Biosystems) consisting of the following targets: 18S-Hs99999901_s1; GAPDH-Hs99999905_m1; ARX-Hs00292465_m1; CHGA-Hs00900370_m1; SYP-Hs00300531_m1; NTS-Hs00175048_m1. is significantly downregulated in patient-derived HIOs (p<0.05) (two-tailed, unpaired t-test). 
Significant gene expression changes in chr17 ΔICR/ΔICR mice and corresponding changes in human gastrointestinal tissues.
